Prader-Willi syndrome (PWS) is a rare, complex multisystem genetic disorder which includes hypothalamic dysfunction, hyperphagia, cognitive and behavioral problems, increased anxiety, and compulsive behaviors. Individuals with PWS have a deficit of oxytocin producing neurons in the paraventricular nucleus of the hypothalamus. Oxytocin plays a role in regulation of feeding behaviors, social interactions, and emotional reactivity, which are all issues that significantly affect the quality of life for individuals with this syndrome. We performed a double-blind, placebo-controlled, crossover study in 24 children with PWS at three academic institutions using 5 days of intranasal oxytocin (IN-OT) or 5 days of intranasal placebo spray, followed by a 4 week washout period, and then patients returned for 5 days of treatment with the alternate source. Questionnaires, including the Aberrant Behavior Checklist, Social Responsiveness Scale, Repetitive Behavior Scale − Revised, and the Hyperphagia Questionnaire, as well as Clinical Global Impression scales were administered. Blood testing for sodium, potassium, and glucose levels on days 2, 4, and 6, and a 24 hr diet recall. All scales factor improvement from Day 3 to Day 6 favored oxytocin over placebo. No single factor showed a statistically significant difference (P < 0.05) between groups at Day 6. The drug effect appeared to be diminished at Day 14. There was no evidence of a difference between oxytocin and placebo in safety lab parameters, 60 min post dose vital signs, weight, or diet parameters. The results from this study suggest that low dose intranasal oxytocin is safe for individuals with PWS and may result in reduction in appetite drive, and improvements in socialization, anxiety, and repetitive behaviors.
brain individuals with PWS and Bittel and colleagues reported decreased oxytocin receptor (OTR) gene function in PWS (Bittel, Kibiryeva, Sell, Strong, & Butler, 2007) . In addition with its well-known anorexigenic effect, OT is involved in establishing and maintaining social standards. In a PWS knock-out mouse model for the Magel2 gene, there is a significant reduction in OT, and the mice with this mutation that live into adulthood have reduced interest in new partners, reduced novel object exploration, and alter special learning deficits (Dombret et al., 2012) . In these mice, a single OT injection at 5 hr of life prevented early death observed in 50% of newborn mice by recovering a normal suck (Schaller et al., 1995) , while daily oxytocin administration from birth to day 7 of life prevented abnormalities in social behavior and special learning deficits (Meziane et al., 2015) .
These findings suggest that cognitive and behavioral phenotypes seen in PWS can be rescued postnatally.
Central release of oxytocin and its closely related peptide, arginine vasopressin (AVP), are involved in aspects of social cognition and function including social recognition, social memory, affiliative behaviors, mother-infant and male-female pair-bond formation, separation distress, and other aspects of social attachment (Bachner-Melman and Ebstein, 2014) . Oxytocin is also involved in regulating stress response and studied extensively because of its unique role in influencing social and repetitive behaviors (Yee et al., 2016) . There is potential to generate animal models with behavioral deficits that may relate to autism. In animal models, oxytocin has been shown to play a critical role in social processing, recognition, and bonding, and also to influence stereotyped behaviors such as exaggerated grooming (Yee et al., 2016) . In mammals, OTRs are expressed at higher levels in early development. OT knockout mice have been shown to maintain olfaction and cognitive performance, but suffer deficits in social recognition that were recovered by intraventricular OT but not by AVP administration (Sala et al., 2011) . Compared to wild-type, OTR knockout mice emit fewer ultrasonic vocalizations in response to social isolation, experience deficits in social discrimination, and demonstrate more aggressive behavior.
The oxytocin system appears to be dysfunctional in individuals with PWS. In adults with PWS, the number of oxytocin-expressing neurons in the hypothalamus was significantly decreased and plasma levels of oxytocin were relatively low in relation to their obesity (Bittel et al., 2007; Swaab et al., 1995) . However, 23 children with PWS between 5 and 11 years of age were noted to have high plasma levels of oxytocin (Johnson, Manzardo, Miller, Driscoll, & Butler, 2016) . As individuals with PWS have symptoms consistent with oxytocin deficiency, including poor suck and swallow as infants, hyperphagia in childhood/adulthood, anxiety, and repetitive behaviors, it is hypothesized that these high serum levels of oxytocin could be due to disruption of the oxytocin receptor responsivity or overproduction of non-biologically active form of oxytocin (Johnson et al., 2016) . If this were the case, then supplementation with the active formulation of oxytocin could be beneficial, even in the face of elevated serum levels of oxytocin.
Several studies in humans have investigated the effects of intranasal oxytocin (IN-OT) . IN-OT is absorbed through the highly permeable nasal mucosa, and shown to pass the blood-brain-barrier, with ease to self-administer. However, the published studies on the effects of IN-OT in PWS are contradictory. In a double blind placebo study of adults with PWS, a single dose of IN-OT significantly decreased depressive mood tendencies and tantrums while increasing trust in others, with supportive data to decrease appetite with higher satiety (Tauber et al., 2011) . These results were recorded for 2 days following a single IN-OT dose administration. However, another study of 30 adolescents and adults with PWS with twice daily dosing of IN-OT found no improvements in behaviour, hyperphagia, or compulsivity, but an increase in temper outbursts with higher doses of oxytocin (Einfeld et al., 2014) .
The need for treatment of hyperphagia and behavioral issues in children with PWS, along with the Magel2 knock-out mice data, and the general safety of IN-OT administration in humans, prompted us to evaluate the tolerance and effects of IN-OT in children with PWS ages 5-11 years who were in nutritional phases 2b or 3 (increased appetite and interest in food).
| MATERIALS AND METHODS
This study was a two period two treatment crossover study with 24 patients randomized equally to receive either IN-OT followed by placebo or placebo followed by IN-OT. A minimum 4 week washout period was required between periods.
Initial studies of an intervention in a new population, especially young children, are always small in sample size. The goal in these studies is not to demonstrate efficacy, but rather to ensure there are no dangerous safety issues and also to potentially test out various instruments and procedures for larger studies (Lancaster, 2015) .
The sample size of this study was based on a prior specified 0.33 difference in an adverse event incidence difference between IN-OT and placebo. It was not anticipated that efficacy measures would show statistical significance, therefore, the emphasis for efficacy was on the observed 95% confidence intervals between IN-OT and placebo administration (Lancaster, Dodd, & Williamson, 2004) .
The study was performed under the auspices of the NIH-funded Rare Disease Center Network at three of the sites designated for study of PWS: University of Florida, Kansas University Medical Center, and University of California, Irvine. Determination of nutritional phase was done by the PI at each site based on the nutritional phases described by this consortium in 2011 (Miller et al., 2011) . Validated questionnaires were used in the study to evaluate the effects of IN-OT on behavior, socialization, and anxiety, including: Aberrant Behavior Checklist (ABC); Repetitive Behavior Scale-Revised (RBS-R) (Lam and Aman, 2007) ; and Social Responsiveness Scale (SRS) (Constantino et al., 2003) . Additionally, the Hyperphagia Questionnaire (HQ) (Dykens, Maxwell, Pantino, Kossler, & Roof, 2007) was administered to determine the effects on appetite in PWS. All questionnaires were modified to reflect that the respondent was answering the questions for the past 24 hr only, as they were used repeatedly during the course of the study. A standardized Clinical Global Impression (CGI) scale was given daily in person by the study coordinator during the study, as well as by phone on Day 14. Assessment of the Clinical Global Improvement (CGI) was based on the results from Day 7 (immediately after completing treatment with IN-OT or placebo) and Day 14 (after they had been off treatment for 1 week).
A 24 hr dietary recall was obtained from parents on Days 2, 4, and 6 during the study and was analyzed by a registered dietitian using the the value is believed to be negligible; 2) the food is usually eaten in very small amounts; 3) it is unknown if the nutrient exists in the food at all; or 4) there is no way to estimate the value because the food is unlike any other. The NDSR software utilizes the multiple-pass system of the interview methodology. The primary caregiver for the child typically provided the report, but review of portion sizes and food types was done with the parents to ascertain, to the extent possible, that the information we received was accurate and complete.
Participants came in within 7 days prior to participating in the study for screening blood work and determination of nutritional phase. Non-fasting blood was collected from each study participant into 6.0 ml K 2 EDTA BD Vacutainer Plus Blood Collection tubes containing either 100 μl of AEBSF (120 mg/ml in water) for the assessment of acylated and un-acylated ghrelin isoforms, or 100 μl of aprotinin (11,063 KIU/ml) for the assessment of cortisol, insulin, leptin, orexin-A, and oxytocin. The samples were then centrifuged within 30 min of collection at 3,000g for 15 min at +4°C. Plasma samples were aliquoted into 1 ml cryo-tubes and stored at −80°C until use.
Cortisol was assayed using an ELISA kit purchased from Abcam, MA. Insulin and leptin were assayed using ELISA kits obtained from EMD Millipore, MA. Concentrations of orexin-A and oxytocin were measured using fluorescent ELISA kits obtained from Phoenix Pharmaceuticals, Inc., CA. Plasma samples were diluted 1:2 in assay buffer for both orexin-A and oxytocin ELISAs. Acylated ghrelin and unacylated ghrelin were measured using ELISA kits purchased from Cayman, MI. Plasma samples were diluted 1:2 and 1:5 in assay buffer for acylated ghrelin and unacylated ghrelin, respectively. On all assays, samples were assayed in duplicates and procedures performed as per instructions of the manufacturer. The ELISA data were normalized for inter-assay variability to three internal controls that were included with every assay performed.
| RESULTS
Twenty four individuals with PWS, ages 5-11 years, participated in this study. Recruitment was rapid with all subjects enrolled within a 6 month time frame. There were no dropouts or withdrawals. There were nine females/15 males. Appropriate genetic testing was used to classify individuals with PWS into the appropriate molecular classpaternal deletion, maternal uniparental disomy (UPD), or imprinting defect (ID) (Buiting et al., 2014; Driscoll et al., 2016) . There were 18 participants with deletion, 5 with UPD, and 1 with ID (Table 1) .
There was no evidence of a difference between oxytocin and placebo in safety lab parameters measured in 60 min post dose vital signs, or in weight. Pre-and post-dose blood pressure, heart rate, temperature, and respiratory rate were not significantly different, nor were they different in those treated with oxytocin versus placebo. The weight of the participants remained stable over the time of evaluation and did not differ between treatment groups (P = 0.396). Sodium levels, blood glucose levels, and insulin levels were all within normal range prior to treatment, and were not significantly different on follow-up measurement on Days 2, 4, and 6. IN-OT had an excellent safety profile in this study with few adverse events reported ( Table 2 ).
The most frequent adverse event with oxytocin versus placebo was nasal irritation (P = 0.125). The only other adverse event noted was irritability (n = 2) and increased irritability (n = 2) on IN-OT, each only occurring 1 day during the study and self-resolved.
Baseline scores and ranges on the questionnaires did not differ between participants at either week of the study. | 1245 intervals appear to be shifted toward zero with two endpoints, hyperphagia behaviors, and the social responsiveness total score now favoring placebo. Shifts toward zero are consistent with the diminishment of study drug effect, as would be expected since they were off of the study drug for one week at the time of evaluation.
The most clinically relevant effect noted by parents with IN-OT compared to placebo was a reduction in anxiety for the participants in nutritional phases 2b and 3. This manifested as decreased selfinjurious behavior (e.g., skin picking, nail biting), as noted on the RBS-R. It is natural to ask whether the changes we saw from baseline with IN-OT compared to placebo could be due to chance. This is difficult to answer precisely because the 17 endpoints are not independent-many measure similar underlying behavior, therefore there is certainly some correlation between endpoints. If we disregard the magnitude of the superiority of oxytocin over placebo, and if the two groups are equivalent on all endpoints, then this is sign test situation with 17 potentially correlated endpoints. When six independent endpoints all indicate superiority or one group over another group, then the sign test is statistically significant at 0.05 Level. Therefore, for the results of this trial to not be considered statistically significant, one would have to believe that the 17 endpoints in this study have less information than six independent endpoints. Whether this is true can be debated however clearly, the results of this trial show a trend toward significance and therefore provide support for a larger study (McGrath, 2013) . Individuals with PWS have dysfunctional behavioural patterns which inhibit normal socialization. They have increased anxiety, stereotypic behaviours, and temper tantrums, which can cause them to have poor relationships with their peers (Tauber et al., 2011) . They also can have difficulties understanding social situations and interpreting social cues (Bull, Oliver, Callaghan, & Woodcock, 2015; Rice and Einfeld, 2015) . Oxytocin nasal spray can enhance emotional recognition processing and also may decrease stereotypic, repetitive behaviours. However, to date there are two published studies evaluating the effects of IN-OT in individuals with PWS-one which showed positive results with a single IN-OT administration (Tauber et al., 2011) , and one which showed no benefits in terms of foodrelated or repetitive behaviours and increased temper outbursts with an 8 week course of IN-OT (Einfeld et al., 2014) .
Given the positive trend on all variables in our study with IN-OT administration, it is possible that the previously published negative results of IN-OT in adults and adolescents with PWS were simply due to an overdose of the hormone (Einfeld et al., 2014) . In animal models there is considerable evidence that oxytocin can bind to and affect receptors for the closely related peptide, arginine vasopressin (AVP);
particularly the V1A receptor subtype (Koenig, Klin, & Schultz, 2004) .
While OT exposure is associated with positive sociality and reduced anxiety, AVP is anxiogenic (Francis et al., 2014; Insel, 2010; Manning et al., 2012) . At higher levels. OT and AVP are partial agonists for their homologous receptors (Wigger et al., 2004) . Thus, the high doses of receptors. It is known that exposure to oxytocin leads to desensitization of the oxytocin receptor in order to protect cells from overstimulation (Conti, Sertic, Reversi, & Chini, 2009 ). This desensitization can occur very rapidly, within seconds or minutes, and is observed in the majority of G protein-coupled receptors, including the oxytocin receptor (Passoni, Leonzino, Gigliucci, Chini, & Busnelli, 2016) . However, studies have shown that these receptors are recycled back to the cell surface once oxytocin levels have decreased (Passoni et al., 2016) . Therefore, it is possible that longer-term, daily dosing could cause the oxytocin receptor to be internalized into the cells and not be able to be recycled to the cell surface. Therefore, it is critical that both longer-term and dose-finding studies be explored in this vulnerable population before clinicians prescribe this medication. An additional concern about longerterm use of oxytocin, is that the oxytocin receptor expression is susceptible to epigenetic changes, as it is modulated by DNA methylation of its promoter (Harony-Nicolas et al., 2014) . Therefore, there is concern that chronic administration of exogenous oxytocin may result in transcriptional silencing of the oxytocin receptor through epigenetic mechanisms.
While we did not find any significant correlations between anorexogenic (orexin-A, leptin, oxytocin) or orexogenic (ghrelin) hormones with IN-OT in this short-term study, the lack of differences could be due to the short time frame in the study or to the methods of measurement used. Future studies of IN-OT in PWS will need to include larger sample sizes, longer duration of treatment with dose-optimization protocols, and determination of the bioavailability of the intranasal oxytocin used in this study.
Evaluations by teachers, therapists, or physicians, in addition to just parental questionnaires would also be beneficial in future studies.
However, the positive results in this short-term study of children with PWS across all of the domains measured, are promising that IN-OT may offer some relief of core PWS symptoms for individuals with this rare genetic obesity-related disorder. However, longer, dosefinding studies are necessary.
